Illegal clinics busted in Panipat, 2 FIRs registered

Karnal: The Chief Minister’s Flying Squad raided two illegally operating clinics in Panipat, leading to the registration of two separate FIRs. The raids revealed serious violations, including individuals running medical facilities without valid licenses, degrees, or regulatory approvals-posing a significant threat to public health.

In the first case, Shabir Ali, a local resident, was booked at the Model Town police station under Sections 18(a)(i) and 18(c) of the Drugs and Cosmetics Act, Section 34 of the National Medical Commission Act, and Section 318(4) of the Bharatiya Nyaya Sanhita (BNS), reports Hindustan Times.

Also Read: Quack who is Class 8 dropout arrested in Ganjam

The raid was carried out following a tip-off received by the Civil Surgeon of Panipat and led by Vishal, a medical officer at the general hospital. Upon entering the clinic, the squad found Shabir Ali seated in the doctor’s chair, claiming he was operating the clinic. While the board displayed the name of Ali’s daughter, a BAMS graduate, who he said moved to Saharanpur after getting married in November 2024.

The team also discovered a large stock of allopathic and injectable medicines, with some bearing the name Dr. S Khan. The fake doctor also failed to present any valid medical qualifications or operating license, prompting the FIR.

In a separate incident, another Panipat resident was found illegally running Dev EH Hospital and Medical Institute near Deswal Chowk. A second FIR was lodged at the Old Industrial police station under similar sections of the Drugs and Cosmetics Act, the National Medical Commission Act, and the BNS.

Also Read: 2 Quacks booked for illegal practice

Speaking to Hindustan Times, Panipat deputy chief medical officer Subash Galawat stated in his complaint that Devender presented certificates claiming a BEMS (Bachelor of Electropathy Medicine Surgery) degree and registration with the Electronomopathy Medical Council, Panchkula.

However, the team determined that these certificates are not recognized by the National Medical Commission or any legally authorized medical body. The FIR notes that the legitimacy of the council issuing these certificates needs verification by appropriate regulatory authorities.

Both individuals are now under investigation for unauthorized medical practice, which could pose serious health risks to unsuspecting patients.

Powered by WPeMatico

Breast Reconstruction in Older Patients Linked to Greater Efficiency, shorter operative time: Study

A new study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery showed that older patients undergoing breast reconstruction tend to have shorter operative times and quicker reconstruction completion compared to younger patients. This may be due to increased patient motivation, fewer aesthetic concerns, or surgeons’ efforts to reduce anesthesia duration in this age group.

Breast cancer treatment is important because it may save lives, improve quality of life, and lessen the effects of this common and sometimes fatal illness. Enhancing the quality of life for survivors is becoming more and more important as breast cancer survival rates rise, and breast reconstruction is a key component of this effort. Even though recent research suggests that age shouldn’t be a deterrent to breast reconstruction following a mastectomy, older women’s use rates are still disproportionately low.

Although reconstruction is performed on over half of mastectomy patients, less than 10% of these individuals are older than 60. Older patients are less likely to use breast reconstruction, even if results and satisfaction are comparable across age groups. Therefore, in order to determine the variables causing this gap, Jacquelyn Roth and team carried out this study to look at age-related disparities in care schedules and surgical length.

From 2017 to 2023, information on individuals undergoing breast reconstruction was gathered. The duration of index and aggregate procedures, the time between the diagnosis of breast cancer and the consultation for plastic surgery (PS), the index reconstructive surgery, and the final reconstructive treatment were among the outcomes. Both absolute age and age-quartile mediated differences in outcomes were examined using multivariate regression.

Q1 (15.8–44.2 years, mean=38, n=415), Q2 (44.2–52.1, mean=48; n=415), Q3 (52.1–60.6, mean=56; n=416), and Q4 (60.6–85.4, mean=67; n=413) were the age-based quartiles (Q) into which 1659 patients were separated. Comorbidity loads, reconstruction modality, and insurance type varied substantially among quartiles, with Q4 patients having the largest burdens.

According to multivariate regression, shorter index (β=−0.002, P=0.019) and aggregate (β=−0.002, P=0.005) procedure durations were predicted by increasing age. In terms of clinical timescales, shorter timeframes between diagnosis and ultimate surgery were predicted by increasing age (β = -0.006, p = 0.013).

When compared to Q1 patients, Q2 (β = -0.263, p = 0.046) and Q4 (β = -0.625, p = 0.021) patients had shorter time between diagnosis and PS consult. Overall, when compared to younger patients, older individuals having breast reconstruction had shorter operating times and faster reconstruction completion times. 

Source:

Roth, J., Godek, M., Yu, B., Fung, E., & Taub, P. J. (2025). Older age may predict expedited care for motivated breast reconstruction patients. Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS, 106, 416–425. https://doi.org/10.1016/j.bjps.2025.05.031

Powered by WPeMatico

FDA Approves First Triple-Drug Polypill for Initial Hypertension Treatment

The FDA has approved Widaplik, a polypill combining telmisartan, amlodipine, and indapamide, for the treatment of hypertension in adults, including as initial therapy. This is the first triple-combination pill approved for first-line treatment in patients likely to require multiple medications to reach blood pressure targets.

WIDAPLIK is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses: a standard dose and two low doses. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. WIDAPLIK, with its three different doses, can deliver the efficacy benefits of a triple mechanism approach early in the treatment pathway with an established safety profile and good tolerability.

Globally recognized treatment guidelines now recommend the use of single pill combination therapy for most patients and acknowledge the benefit of early use of combination therapy.

In the US, nearly half of adults have hypertension and only around one in four have their blood pressure under control. Hypertension is a major risk factor for coronary heart disease, stroke and heart failure and is estimated to cause 460,000 deaths in the US each year.

Mark Mallon, Chief Executive Officer of George Medicines, said: “Data show that most patients with hypertension will require two or more medicines to bring their blood pressure under control. WIDAPLIK can provide patients with hypertension, including those who are starting treatment, with a different approach to control their blood pressure. With its triple combination efficacy, established safety profile, good tolerability and its availability in a single pill, WIDAPLIK has the potential to address key challenges in current hypertension treatment approaches. With planning underway for the upcoming US commercial launch of WIDAPLIK, and further regulatory submissions in other territories anticipated during 2025, George Medicines is well-positioned to positively impact the global burden of hypertension.”

Dr. Paul Whelton, Show Chwan Chair of Global Public Health at Tulane University, New Orleans, Louisiana, and Past President of the World Hypertension League, said: “I am very excited and pleased to have WIDAPLIK approved for the treatment of hypertension in the US. Single pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide. Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with WIDAPLIK offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment.”

The FDA approval is based on positive results from two international Phase 3 trials, which compared WIDAPLIK against placebo and against dual combinations of its component drugs.

In both trials WIDAPLIK significantly improved blood pressure and control rates vs comparators. In clinical trials, the most common adverse event reported in patients treated with WIDAPLIK is symptomatic hypotension. WIDAPLIK is contraindicated in patients with anuria, known hypersensitivity to telmisartan, amlodipine, indapamide, or to other sulfonamide-derived drugs, or to any other component of this product. In patients with diabetes, WIDAPLIK is not to be co-administered with aliskiren. A boxed warning in the labeling informs physicians and patients to discontinue WIDAPLIK as soon as possible after pregnancy is detected due to fetal toxicity. For full Prescribing Information, visit here.

The US commercial launch of WIDAPLIK is anticipated in Q4 2025.

George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company’s WIDAPLIK development program built on earlier research by The George Institute, including the 700-patient TRIUMPH trial undertaken in Sri Lanka in 2016/17, which found that among patients with mild to moderate hypertension, treatment with a low-dose triple combination pill led to an increased proportion of patients achieving their target blood pressure goal versus usual care.

Powered by WPeMatico

High Eosinophil Counts in COPD Patients Tied to Increased Risk of Heart Failure and Kidney Disease: Study Shows

China: A new study published in BMC Pulmonary Medicine highlights a significant association between elevated blood eosinophil counts and the presence of extrapulmonary health conditions in individuals with chronic obstructive pulmonary disease (COPD). Conducted by Dr. Hong Chen and colleagues from Chengdu Second People’s Hospital and Sichuan University, the research suggests that eosinophilic inflammation may contribute to systemic complications in COPD beyond the well-known respiratory effects.

The researchers analyzed data from the U.S. National Health and Nutrition Examination Survey (NHANES) covering 2013 to 2018. The study focused on 614 adults diagnosed with COPD, categorizing them based on their blood eosinophil counts (BEC): those with levels below 300 cells/μL and those with levels at or above this threshold.

The study led to the following findings:

  • Patients with elevated eosinophil counts (≥300 cells/μL) had a significantly higher prevalence of extrapulmonary comorbidities than those with lower counts.
  • 85.3% of individuals in the high-eosinophil group had at least one extrapulmonary condition versus 71.4% in the low-eosinophil group.
  • After adjusting for potential confounders, high eosinophil levels were associated with a two-fold increase in the odds of having any extrapulmonary comorbidity (OR 2.03).
  • Elevated eosinophil counts were linked to a 69% higher risk of congestive heart failure (OR 1.69).
  • High eosinophil levels were also associated with nearly double the risk of renal dysfunction (OR 1.95).
  • There was no significant association between eosinophil levels and pulmonary comorbidities.
  • The findings suggest that eosinophilic inflammation may play a role in systemic health issues beyond the respiratory system.

“Our analysis indicates that higher eosinophil counts in COPD patients may serve as a signal for non-respiratory complications, particularly involving the cardiovascular and renal systems,” noted the authors.

To strengthen their findings, the researchers conducted sensitivity analyses using additional eosinophil cutoffs, which consistently confirmed the association between rising eosinophil levels and increased risk of extrapulmonary disease.

The authors emphasized the potential clinical implications of these results, suggesting that therapies targeting eosinophilic inflammation might benefit lung function and help mitigate broader health risks in COPD patients. However, they called for further prospective studies to explore causal pathways and determine how best to incorporate eosinophil monitoring into comprehensive COPD management strategies.

“The study highlights the importance of viewing COPD as a systemic disease and not just a condition of the lungs, especially when elevated eosinophil levels are present,” the authors concluded.

Reference:

Chen, H., Hu, X., He, C. et al. Association of blood eosinophil counts with pulmonary and extrapulmonary comorbidities in patients with chronic obstructive pulmonary disease: data from NHANES 2013–2018. BMC Pulm Med 25, 256 (2025). https://doi.org/10.1186/s12890-025-03734-6

Powered by WPeMatico

Higher long-term variability of serum uric acid associated with diabetic retinopathy risk: Study

A new study published in the journal of Diabetes Research and Clinical Practice found that patients with type 1 and type 2 diabetes mellitus had a greater chance of developing diabetic retinopathy (DR) if their serum uric acid levels were variable.

With a projected global incidence of 12.2% in 2045, diabetes mellitus (DM), a metabolic condition marked by persistent hyperglycemia brought on by absolute or relative insulin insufficiency, has emerged as one of the most prevalent chronic illnesses. Diabetes-related hyperglycemia and other metabolic irregularities can have a significant impact on the body’s organs, resulting in retinopathy, nephropathy, and neuropathy, among other problems.

One significant ocular consequence of diabetes is DR, which affects 22.27 percent of people with diabetes. Additionally, 6.17 percent of people with diabetes have vision-threatening DR (VTDR), making DR the most common cause of visual impairment in people of working age.

Purine metabolism produces uric acid, and high blood uric acid levels are a frequent metabolic change seen in diabetic patients. Several clinical investigations have linked higher serum uric acid levels to diabetic retinopathy. Thus, this study assessed the relationship between the onset and/or severity of diabetic retinopathy (DR) in patients with Type 1 and Type 2 diabetes mellitus (DM) and the variability of serum uric acid (SUA).

At Shanghai General Hospital, 730 DM patients lacking proliferative diabetic retinopathy at baseline participated in a prospective trial. Every subject had several DR evaluations using fundus photography and SUA measures throughout the course of at least a year of follow-up. To evaluate SUA fluctuations, average real variability (ARV) was computed for every patient, taking into consideration different follow-up frequencies and visit counts.

With a Log-rank p-value of 0.0055, the Kaplan-Meier survival analysis revealed that the group with higher SUA ARV scores had a greater chance of developing and progressing DR.

The hazard ratios for DR deterioration in patients in the third and fourth quantiles of ARV are 2.2 (p = 0.008, 95 % CI: 1.2206∼3.8201) and 2.74 (p = 0.017, 95 % CI: 1.1339∼3.7255), respectively, as compared to patients in the first quantile, according to Cox regression with Backward Stepwise Selection of covariates.

Overall, in DM patients, high long-term variability is strongly linked to the onset and exacerbation of DR, indicating the significance of the advantages of ongoing serum uric acid management.

Source:

Zhu, Q., Wang, H., Qu, Y., Jiang, Y., Liu, X., Liu, X., Xiao, Y., Lv, K., Xing, X., Niu, T., & Liu, K. (2025). Association between long-term serum uric acid variability and diabetic retinopathy: A prospective study in patients with Type 1 and Type 2 diabetes. Diabetes Research and Clinical Practice, 226(112306), 112306. https://doi.org/10.1016/j.diabres.2025.112306

Powered by WPeMatico

High dietary fiber intake may reduce likelihood of stroke, death, reveals research

A recent study published in Stroke by Lai et al. (2025) highlights a significant association between high dietary fiber intake and reduced mortality from stroke. The research indicates that individuals consuming higher amounts of dietary fiber have a lower risk of dying from stroke compared to those with lower fiber intake. This finding aligns with previous studies that have demonstrated the protective effects of dietary fiber against cardiovascular diseases, including stroke.

The study emphasizes the importance of incorporating fiber-rich foods into the diet, such as fruits, vegetables, whole grains, and legumes. These foods not only provide essential nutrients but also contribute to overall cardiovascular health. The mechanisms by which dietary fiber exerts its protective effects include the reduction of blood pressure, improvement of lipid profiles, and enhancement of insulin sensitivity. In addition to the findings by Lai et al., a meta-analysis by Threapleton et al. (2013) supports the inverse relationship between dietary fiber intake and stroke risk. Their analysis concluded that greater dietary fiber consumption is significantly associated with a lower risk of first stroke, reinforcing the importance of dietary fiber in stroke prevention strategies. Given the substantial evidence linking dietary fiber intake to reduced stroke mortality, public health initiatives should focus on promoting diets rich in fiber. Such dietary modifications are a cost-effective and accessible means to improve cardiovascular health and reduce the burden of stroke-related deaths.
Keywords: dietary fiber, stroke mortality, cardiovascular health, whole grains, fruits, vegetables, stroke prevention
References:

Lai, S., et al. (2025). High dietary fiber intake may reduce likelihood of stroke death. Stroke. doi:10.1161/STROKEAHA.124.049093

Powered by WPeMatico

Low Vitamin D3 and High Prolactin Linked to Increased Uterine Fibroids in Premenopausal Women: Indian Study

India: A new study published in the Indian Journal of Medical Sciences sheds light on the hormonal imbalances potentially influencing the growth and progression of uterine fibroids (UFs) in premenopausal women. Conducted by Dr. Azaz Ahmad and colleagues from the Department of Reproductive Medicine, Indira IVF Hospital Pvt. Ltd., Udaipur, India, the research explored the correlation between serum vitamin D3 and prolactin (PRL) levels in women diagnosed with uterine fibroids.

“Indian study found that premenopausal women with uterine fibroids had much lower vitamin D3 levels (10.85 ng/mL) and higher prolactin levels (27.79 ng/mL) compared to healthy women (19.64 and 13.96 ng/mL, respectively). Lower vitamin D3 was linked to more fibroids, while higher prolactin levels were also associated with an increased number of fibroids, suggesting both may play a role in fibroid development,” the researchers reported.

Uterine fibroids, also known as leiomyomas, are non-cancerous tumors commonly seen in women of reproductive age, with prevalence rates nearing 70%. Despite being benign, these growths can lead to a range of reproductive and gynecological issues, including infertility, pelvic pain, and heavy menstrual bleeding. Emerging evidence points to the role of vitamin D deficiency and elevated prolactin levels in the development and exacerbation of these tumors.

In this cross-sectional study conducted between April and November 2022, researchers compared 80 premenopausal women with uterine fibroids (≥2 cm in size) with 80 healthy women. All participants were evaluated using transvaginal ultrasound and underwent blood tests to measure serum levels of vitamin D3 and prolactin.

Based on the study, researchers reported the following findings:

  • Women with fibroids had significantly lower serum vitamin D3 levels (10.85 ± 3.34 ng/mL) compared to healthy controls (19.64 ± 5.50 ng/mL).
  • Prolactin levels were significantly higher in the fibroid group (27.79 ± 8.19 ng/mL) than in the control group (13.96 ± 4.09 ng/mL).
  • Both differences in vitamin D3 and prolactin levels between groups were statistically significant.
  • Serum vitamin D3 levels showed a moderate negative correlation with the number of fibroids (r = −0.513), indicating that lower vitamin D3 levels were linked to a higher number of fibroids.
  • Serum prolactin levels exhibited a positive correlation with fibroid number (r = 0.453), suggesting that higher prolactin levels were associated with a greater fibroid burden.

These findings highlight the potential role of vitamin D3 deficiency and elevated prolactin as contributing factors in fibroid development. The authors suggest that monitoring these serum levels could aid in early detection and better management of uterine fibroids in premenopausal women.

“Given the clear associations observed, serum vitamin D3 and prolactin may serve as important biomarkers in the clinical evaluation of uterine fibroids,” the researchers noted.

The study adds to growing evidence supporting the importance of hormonal and nutritional assessment in women with fibroids. It paves the way for future interventions aimed at correcting these imbalances to slow disease progression.

Reference:

Ahmad A, Ahmad M, Bhoi NR, Kumar M. Correlation between serum vitamin D3 and prolactin levels in premenopausal women with uterine fibroids. Indian J Med Sci. doi: 10.25259/IJMS_246_2024

Powered by WPeMatico

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer: Study

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.

Now, new research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer-and with a specific genetic makeup called deficient DNA mismatch repair (dMMR)-was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone. Approximately 15% of people diagnosed with colon cancer exhibit dMMR and, to date, these tumors appear less sensitive to chemotherapy. The results of the multi-center study were presented during a plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

“The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer,” says oncologist Frank Sinicrope, M.D., who led the study. “It’s extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival.”

Until now, the standard treatment after surgery for any stage 3 colon cancer has been chemotherapy. However, the researchers note that approximately 30% of patients experience cancer recurrence despite this treatment.

The clinical trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. The immunotherapy given in this study was an immune checkpoint inhibitor, known as atezolizumab, which activates one’s immune system to attack and kill cancer cells, which are responsible for cancer recurrence and spread. The patients-who lived in the U.S. and Germany-received chemotherapy for six months along with immunotherapy and then continued with immunotherapy alone for another six months.

Dr. Sinicrope and others previously studied patients with colon cancer whose cells are unable to repair errors during DNA replication that create a nucleotide mismatch, a condition called dMMR. They noted that these patients’ tumors showed a striking increase in inflammatory cells within the tumor, including those that express the target of immune checkpoint inhibitors. This sparked the idea of using immune checkpoint inhibitors to make the immune cells more effective in attacking and killing the cancer cells.

Based on the data from this study, Dr. Sinicrope recommends this combination of immunotherapy and chemotherapy treatment to be the new standard treatment for stage 3 deficient mismatch repair colon cancer. The research team plans to approach the National Comprehensive Cancer Network, a nonprofit organization consisting of 33 leading cancer centers, including Mayo Clinic, with this recommendation.

The study included patients with Lynch syndrome, the most common form of hereditary colon cancer, as these patients can have tumors that show deficient mismatch repair (dMMR).

“We’re changing the paradigm in colon cancer treatment. By using immunotherapy at earlier stages of disease, we are achieving meaningful benefits for our patients,” says Dr. Sinicrope.

Reference:

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer, Mayo Clinic, Meeting: 2025 ASCO Annual Meeting.

Powered by WPeMatico

Increasing Antioxidant Intake May Help Preserve Gum Health and prevent periodontitis: Study

Elevated dietary antioxidant intake is associated with a diminished prevalence of periodontitis suggests a new study published in the BMC Oral Health.

The antioxidant system of periodontal tissue is unbalanced in periodontitis, and appropriate supplementation of antioxidants can effectively prevent or alleviate periodontal tissue damage. However, a dearth of research exists on the association between dietary antioxidant intake and the prevalence of periodontitis. Six dietary antioxidants (vitamins A, C, and E, zinc, selenium, and carotenoids) were extracted from two 24-h recall interviews utilizing data from the National Health and Nutrition Examination Survey (NHANES) conducted between 2009 and 2014. The composite dietary antioxidant index (CDAI) made calculations using data on the intake of these six dietary antioxidants. Periodontitis severity was categorized into mild, moderate, and severe classifications based on established consensus criteria. Additionally, a restricted cubic spline (RCS) regression model was applied to evaluate the potential non-linear dose–response relationship between CDAI and periodontitis prevalence. Results: A total of 9,378 adults were included in this analysis, of which 4,755 had periodontitis. Individuals within the highest CDAI quartile demonstrated a diminished prevalence of total periodontitis compared to those in the lowest quartile (OR = 0.70 [0.53–0.93], Ptrend = 0.012). When moderate/severe periodontitis served as the outcome variable, those within the fourth CDAI quartile exhibited a 32% reduced prevalence compared to those in the first quartile (OR = 0.68 [0.52–0.88], Ptrend = 0.006). RCS regression showed that CDAI was linearly and negatively related to the prevalence of periodontitis (both total and moderate/severe periodontitis). In subgroup analysis by gender, a significant association between CDAI and total periodontitis was discerned solely among females (OR = 0.60 [0.42–0.85], Pinteraction = 0.015). Elevated dietary antioxidant intake is associated with a diminished prevalence of periodontitis. These findings underscore the potential role of antioxidants in periodontal health.

Reference:

Chen, X., Han, R., Liu, X. et al. Association between composite dietary antioxidant index and the prevalence of periodontitis: results from NHANES 2009–2014. BMC Oral Health 25, 779 (2025). https://doi.org/10.1186/s12903-025-06151-7

Keywords:

BMC Oral Health, Chen, X., Han, R., Liu, X, Periodontitis, Antioxidants, Dietary intake, CDAI, NHANES

Powered by WPeMatico

Higher Vitamin D Levels Linked to Reduced Mortality and Cardiovascular Disease Risk in Psoriasis Patients: Study

Researchers have identified in a new study that increased serum 25-hydroxyvitamin D (25(OH)D) is linked with lower risks of all-cause mortality and cardiovascular disease (CVD) in psoriasis patients. The large cohort study, including 8,947 patients with psoriasis and 178,937 age- and sex-matched controls from the UK Biobank, was conducted to examine the protective effect of serum 25(OH)D against mortality and the risk of CVD in psoriasis patients. The study was published in the Journal of the American Academy of Dermatology by Kaiqing Lin and colleagues.

Psoriasis is a chronic inflammatory skin disease that has been associated with an elevated risk of systemic illnesses, including CVD. Vitamin D, with its immune-modulatory and cardiovascular functions, has been implicated in protection against diseases. Yet, there has been limited evidence demonstrating the effect of serum 25(OH)D levels on mortality and risk of CVD among psoriasis patients. This research sought to fill this gap in knowledge by examining the relationship between levels of serum 25(OH)D and these health outcomes.

This cohort study employed UK Biobank data comprising 8,947 patients with psoriasis and 178,937 controls matched to them. Baseline measurements of serum 25(OH)D were made, and the incidence of CVD and all-cause mortality was followed up. Multivariable-adjusted Cox proportional hazards regression analyses were employed to evaluate the associations of serum 25(OH)D concentrations with mortality risk and CVD.

Key Findings

  • Among patients with psoriasis, patients with the highest serum levels of 25(OH)D (≥50 nmol/L) had a 46% reduced risk of all-cause mortality (HR 0.54) and a 22% reduced risk of new-onset CVD (HR 0.78) relative to those with the lowest levels of vitamin D (<25 nmol/L).

  • Psoriasis patients who had serum 25(OH)D levels ≥50 nmol/L did not have an increased risk of mortality or new CVD events relative to matched controls.

Increased serum 25(OH)D concentrations were also linked with decreased risks for all-cause mortality and CVD in patients with psoriasis.These findings bring to light the importance of maintaining proper levels of vitamin D to promote better health in patients with such conditions. Further research is needed to determine why there is such a protective effect and whether supplementation with vitamin D would result in further improvement in patients with psoriasis.

Reference:

Lin, K., Miao, Y., Gan, L., Zhao, B., Fang, F., Wang, R., Chen, X., & Huang, J. (2025). Associations of serum 25-hydroxyvitamin D concentrations with risks of mortality and cardiovascular disease among individuals with psoriasis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.05.1380

Powered by WPeMatico